![tirzepatide sglt2 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial but also potentially boosting metabolic health sglt-2_inhibitors [TUSOM | Pharmwiki]](https://www.thelancet.com/cms/10.1016/S0140-6736(21)01443-4/asset/ec38c14e-b8b1-438c-81bb-caf4c97dc61c/main.assets/gr2.jpg)
tirzepatide sglt2 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial but also potentially boosting metabolic health sglt-2_inhibitors [TUSOM | Pharmwiki]
USD23.76
USD51.76
Pay in 4 interest-free payments of $5.94 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
![tirzepatide sglt2 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial but also potentially boosting metabolic health sglt-2_inhibitors [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/sglt2.png)
![tirzepatide sglt2 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial but also potentially boosting metabolic health sglt-2_inhibitors [TUSOM | Pharmwiki]](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=122164131782855892)
![tirzepatide sglt2 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial but also potentially boosting metabolic health sglt-2_inhibitors [TUSOM | Pharmwiki]](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01733-2/MediaObjects/41591_2022_1733_Fig1_HTML.png)
![tirzepatide sglt2 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial but also potentially boosting metabolic health sglt-2_inhibitors [TUSOM | Pharmwiki]](https://www.mdpi.com/jcm/jcm-14-00428/article_deploy/html/images/jcm-14-00428-g001.png)
![tirzepatide sglt2 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial but also potentially boosting metabolic health sglt-2_inhibitors [TUSOM | Pharmwiki]](https://www.thelancet.com/cms/10.1016/S2213-8587(22)00188-7/asset/2c20a909-3c0e-4be2-9bc4-c699b73fc56e/main.assets/gr2_lrg.jpg)
![tirzepatide sglt2 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial but also potentially boosting metabolic health sglt-2_inhibitors [TUSOM | Pharmwiki]](https://cardiovascularbusiness.com/sites/default/files/2022-05/tirzepatide_mounjaro_eli_lilly.jpg)
